Published in Lab Law Weekly, January 6th, 2006
According to the data, pharmaceutical companies allocate anywhere from 5.6% (for niche brands) to 12.4% (for blockbuster brands) less of their marketing budget toward advertising in Europe.
Although drug companies may maintain a lean advertising bill in Europe, they make up for it by deploying other promotional tactics. For instance, rather than overspend in direct-to-consumer advertising expenses, European pharmaceutical marketers refocus strategies by aligning the budget...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly